Phase 3 Trials Show Atacicept, Telitacicept, and Sibeprenlimab Transform IgA Nephropathy Treatment
New phase 3 clinical trial data reveal that three drugs targeting APRIL and BAFF pathways—atacicept, telitacicept, and sibeprenlimab—significantly stabilize kidney function and slow disease progression in immunoglobulin A (IgA) nephropathy, … Read More